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ABSTRACT
Objectives: The the study was to estimate the concentrations of antiapoptotic sFas and pro-apoptotic FasL in the serum 
of pregnant women in the third trimester of pregnancy and in the cord blood serum of neonates from vein and arteries 
separately. The correlation could be crucial for evaluation of apoptosis process intensity in placenta and the role of fetal 
blood circulation system on distribution of sFas and FasL.
Material and methods: The study group consisted of 28 pregnant women in physiological pregnancy, between 38– 
–41 weeks. Vein blood was taken from maternal elbow vein and umbilical cord, separately from vein and arteries. The 
research was done by sets for sFas and FasL from R&D Systems Elisa kit.
Results: In arterial and vein cord blood there were much more lower concentrations of sFas than in maternal blood-arterial 
cord blood 3351.78 pg/mL, vein cord blood 3351.78 pg/mL versus maternal blood 5769.62 pg/mL (p < 0.001). No differ-
ence was found in sFas concentrations between cord arterial and vein blood sera. Statistical difference was found between 
mean concentration of Fas ligand in maternal blood serum (71.36 pg/mL) and arterial cord blood serum (164.57 pg/mL) 
p < 0.05 (p = 0.001). Cord arterial blood serum showed much higher concentrations of FasL than maternal blood serum. 
No difference was found between cord arterial and vein blood sera concentrations of FasL: 164.57 pg/mL vs. 170.00 pg/mL 
(p = 0.701).
Conclusions: Obtained results suggest no influence of sFas and FasL production on fetal organism apoptosis. Lowering 
of sFas concentration in fetal blood could mean the increase of apoptosis in fetal organism compared to maternal. Higher 
concentration of FasL in cord blood than in mothers suggests higher apoptosis intensification in fetal circulation and no 
influence of blood flow across placenta on its concentration.
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INTRODUCTION
Soluble Fas and Fas ligand are molecules that take part 
in apoptotic processes. Apoptosis is complicated and mul-
tifactor process which by cytotoxic path causes cell death 
to eliminate destroyed, old or mutated cells. The process in 
physiological conditions constitutes anti-cancer defense 
that is lowered in individuals suffering from cancerous dise-
ases [1, 2, 4, 5]. Apoptosis is necessary in remodeling of ma-
ternal deciduas, to maintain proper maternal–fetal immune 
tolerance and trophoblast invasion into spiral arteries. In 
the course of pregnancy modulation of immune response 
occurs to prevent pregnancy from rejection of allogenic 
graft. Immunomodulation could be connected to changes 
in apoptosis intensification and could cause lowering this 
processes [1–4]. In the course of pregnancy increase of 
vascular bed capacity and growing need of oxygen trans-
porting molecules could cause slowing down apoptosis 
processes in bone marrow. This fact allows longer life of red 
blood cells, protecting pregnant women from anemia [3, 5].
Fas/APO-1/ CD 95 is membrane receptor from tumor ne-
crosis factor (TNF) family because of death domain presence. 
To initiate apoptosis process it is necessary to incorporate 
to Fas molecule of Fas ligand-FasL/CD95L/. System Fas/FasL 
is crucial in surviving of cells, especially neoplastic cells, in 
promotion and protection of cancerous stem cells and in 
the immune elimination of virus-infected and cancerous 
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cells. Higher levels of Fas/FasL were observed in individu-
als suffering from immune system and cancerous diseases 
[6, 7]. It has been shown that the stress-induced expres-
sions of Fas and FasL are dependent on the activation of 
various signaling molecules such as p53, nuclear factor-
-kappa B, specificity protein-1, and early growth response 
factors. Cytotoxic effect as defragmentation of DNA chain is 
depended on the cell cycle phase and is strongest presented 
in indifferent cells and could be observed in cord blood due 
to presence of stem cells [6, 7].
Activation of Fas/FasL system not only induces apoptosis 
but also protects trophoblast from maternal immune sys-
tem. Fas/FasL system protects migration of activated leuco-
cytes between mother and fetus, conversely soluble Fas-sFas 
could act by other mechanism by slowing down apoptosis, 
protecting different cells and activated lymphocytes T from 
apoptosis [6]. Presence of FasL is high in immunopriviledged 
tissues and cells as leucocytes and placenta. One of the most 
important factors that influences the increase of proapop-
totic processes is membrane Fas receptor [7]. 
Soluble Fas [sFas] is formed in the process of alternative 
folding of Fas mRNA. As the effect new protein molecule is 
formed that contains deletion or incompetent trans-mem-
brane domain. In addition sFasL is proteolytic product of 
FasL disintegration and its concentration may be in pro-
portion to intensity of apoptotic processes [8]. We could 
hypothesize that high concentration of sFas correlates with 
decrease of apoptotic process. Probably to increase this 
process higher concentrations of FasL are needed because 
of less affinity to this ligand. 
This suggestion was investigated by Nagata et all., but 
the relationship between the membrane and soluble forms 
of Fas and FasL (sFa, sFasL) is still unknown. Authors sugge-
sted that soluble Fas has a suppressive effect on Fas/FasL-
-mediated apoptosis [9, 14].
Soluble Fas inhibits Fas ligand before getting to recep-
tor and slowed down Fas dependent apoptosis. SFas in late 
pregnancy could probably be synthesized in fetal cells and 
transferred by fetal cord blood into placental bed. Low con-
centration of soluble Fas in first trimester of pregnancy as 
immunotolerance phenomenon could be changed in late pre-
gnancy [9, 10]. Knowledge that placental apoptosis increases 
due to pregnancy development suggests that the best time 
to evaluate sFas and FasL concentrations we can expect in the 
late pregnancy [11]. There is only few existing data describing 
value of sFas and FasL in maternal blood and cord blood in 
third trimester of pregnancy [8–11]. Different than physiologi-
cal concentrations of those molecules could indicate the risk 
of placental dysfunction or immunotolerance failure [10, 11]. 
It is still unclear if in late pregnancy we can expect in-
creased risk of allograft rejection or placental dysfunction 
caused, for example, by high concentration of FasL or lo-
wering concentration of sFas. Different concentrations of 
sFas in fetal circulation from cord artery to vein could give 
an answer of its potential role and distribution in feto-pla-
cental unit and its origin
Aim fo the study
The aim of the study was to estimate concentration of 
two molecules antiapoptotic sFas and pro-apoptotic FasL in 
serum of pregnant women in third trimester of pregnancy 
and in cord blood serum of neonates from vein and arteries 
separately. The correlation could be crucial for evaluation of 
apoptosis processes intensity in placenta and the role of fetal 
blood circulation system on distribution of sFas and FasL.
MATERIAL AND METHODS
The study was conducted in High Risk Pregnancy Unit 
Medical University Lodz in 2014–2015. The study was ap-
proved by University Bioethics Board — approval number 
RNN/149/09/KE. Patients written consent was obtained from 
every patient.
The study group consisted of 28 pregnant women in 
third trimester of uncomplicated pregnancy and proper 
fetal development. Maternal age was between 24–38 years 
and the proportion of primiparous women to multiparous 
as about 2:1. All pregnancies are at term. Gestational age 
was estimated using antenatal ultrasound scan at 12–14 we-
eks. All patients included to the study delivered by elective 
caesarian section because of non perinatal indications. 
Vein blood was taken from 2 to 4 hours before caesa-
rian section from elbow vein. Umbilical cord blood was taken 
separately from vein and from arteries after neonate was 
separated, from placental part of umbilical cord. 
The volume of blood samples was no less than 5 mL 
each. The samples were placed in tubes without antico-
agulation factor and stored in room temperature for about 
60 minutes — to complete coagulation. After formation 
of clots samples were centrifugated for 15 minutes RCF 
389. After centrifugation supernatant of blood samples 
was replaced into Eppendorf tubes then frozen and stored 
at –70°C until the measurement procedure.
The research was done by R&D Systems Elisa kit ac-
cording recommended by producer schemes. SFas was 
measured by Fas Elisa kit (catalog number — DFS00). The 
minimum detectable dose (MDD) of sFas ranged from 31.2 to 
2,000 pg/mL. The sensitivity was 20 pg/mL. The serum con-
centration of Fas was expressed in pg/mL.
FasL was measured by FasL Elisa kit (catalog number 
— DFL00). The minimum detectable dose (MDD) ranged 
from 15.6 to 1,000 pg/mL. The sensitivity was 8.05 pg/mL. 
The serum concentration of FasL was expressed in pg/mL.
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Statistical analysis
 Data base was prepared on calculation spreadsheet pro-
gram Microsoft Excel 2014.Statistical calculations were done 
using statistics software SPSS 14.0 and MS Excel 2014. In 
the study group the results of measured parameters were 
estimated by arithmetic means, standard deviation, maximal 
and minimal values. Data comparisons were analyzed by 
one-way ANOVA . P value < 0.05 was considered to indicate 
statistical significance.
Study group
The study group consisted of 28 healthy pregnant wo-
men in 3rd trimester of pregnancy. Mean age of patients 
was estimated at 32.17 (sd 4.23) years, minimum age was 
24 years and maximum 38 years. The shortest gestational 
age was 38 weeks, the longest was 41 weeks. Mean gesta-
tional age was 39.1 weeks (sd 0.71).
RESULTS
In study group concentration of sFas was measured 
in maternal blood serum and in umbilical cord right after 
delivery by cesarean section, separately for arterial and vein 
blood serum. The results are presented in pg/mL on the 
graph below (Fig. 1). 
Mean value of sFas in maternal blood was 
5769.62 pg/mL (sd = 457.72). Minimal value 5183.51, maxi-
mal 6857.92 pg/mL. In cord blood mean value of sFas ob-
tained from vein was 3251.38 pg/mL (sd = 672.31), minimal 
concentration 2244.03 maximal 4349.45 pg/mL. The result 
of mean sFas concentration obtained from arterial cord 
vessels was 3351.78 pg/mL (sd = 1172.20), minimal value 
was 1812.98 and maximal 5647.66 pg/mL.
Producer suggestion is that in adult human serum sFas 
concentration started from 4792 to 17150 pg/mL. According 
to presented extreme values sFas concentration in maternal 
blood serum samples comprise in those values. In arterial 
cord blood all samples presented lower values, in opposite 
in vein cord blood were in 15.4% of results presented normal 
range and the rest of the results –84.6% were lower than the 
lowest normal range. That meant lower fetal concentration 
of this molecule than normal in adults organism.
In arterial and vein cord blood there were much 
more lower concentration of sFas than in maternal blo-
od-arterial cord blood 3351.78 pg/mL and vein cord blo-
od 3351.78 pg/mL versus maternal blood 5769.62 pg/mL 
(p < 0.001). Statistical analysis was done by Kruskal-Wallis 
test and U Mann-Whitney test and by ANOVA variance. 
Significant difference of sFas value between maternal 
and cord blood was detected. In maternal blood we obse-
rved higher concentration of sFas than found in vein cord 
blood , p was lower than 0.05 (p = 0.013). Variances were 
not similar.
Arterial cord blood serum concentration of sFas was 
also significantly lower than in maternal serum. Statistical 
difference was found in mean sFas concentration comparing 
maternal blood serum to vein cord blood serum (p < 0.001). 
No difference in sFas concentration was found between 
neonate cord arterial serum and vein blood serum (p = 0.98).
Graph below presents results of Fas ligand concentra-
tions in maternal and cord blood sera (Fig. 2). 
Mean value of FasL in maternal blood serum was 
71.36 pg/mL (sd = 15.14). Minimal value 52.69, maximal 
106.99 pg/mL. In cord blood mean value of FasL obtained 
from cord vein serum was 170.00 pg/mL (sd = 57.45), mini-
mal concentration 37.93 maximal 261,226 pg/mL. The result 
of mean FasL concentration in serum obtained from arterial 
cord vessels was 164.57 pg/mL (sd = 52.82), minimal value 
was 35.80 and maximal 226.90 pg/mL.
Producer suggests that in adult human serum FasL con-
centration started from 39.8 to 145 pg/mL. According to pre-
sented extreme values FasL concentration in maternal blood 
samples was in many cases different than expected valu-
es. Cord blood serum concentration taken from arterial ves-
sels in 7.7% of cases was lower than producers’ suggestion 
Figure 1. Concentration of soluble Fas in maternal and cord blood 
sera expressed in pg/mL
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but 61.6% of the results were higher, the rest — 30.7% was 
between concentrations limits suggested by producer. 
Cord vein blood serum in 23.1% of samples presented 
normal range of concentration, 69.2% results were higher 
than norms and 7.7% were much lower concentration of 
FasL.
In cord blood serum taken from arteries and vein more 
results of high concentration were observed than in ma-
ternal blood.
Using analysis of variance ANOVA significance of FasL 
concentration between maternal and cord blood was 
estimated. Significance was lower than 0.05 (p = 0.005). 
Variances were not similar. Measuring by non parametric 
U Mann-Whitney test FasL in maternal blood and comparing 
to vein cord blood statistical difference was found between 
mean concentrations p < 0.05 (p = 0.001). U Mann Whitney 
test shows statistical difference between mean concentra-
tion of Fas ligand in maternal blood serum (71.36 pg/mL) 
compared to arterial cord blood serum (164.57 pg/mL). Cord 
arterial blood serum showed much higher concentrations of 
FasL than in maternal blood serum. No difference was found 
between cord arterial and vein blood sera concentration of 
FasL 164.57 pg/mL vs. [170.00 pg/mL] (p = 0.701).
Vein cord blood serum presents higher FasL concen-
trations than observed in those obtained from maternal 
blood serum. 
DISCUSSION
Analysis of the soluble Fas [sFAS] results obtained from 
maternal blood serum shows that all results were compa-
rable with standards showed by producer. We didn’t find 
higher results than 6851 pg/mL and this observation poin-
ted that expected values of sFas concentration in pregnant 
women is much lower than high normal concentrations.
If we compare our results to those obtained by Velore 
and all our results were much higher than in healthy non pre-
gnant women and in third trimester of pregnancy [11, 12].
This observation is coherent with results of Nagata sug-
gested that soluble Fas has a suppressive effect on Fas/FasL-
-mediated apoptosis [9, 12]. Maybe we could expect lower 
intensification of apoptosis for example in placenta. In one 
observation levels of sFas and FasL were calculated in second 
trimester of pregnancy in amniotic fluid and authors found 
no differences between small for gestational age (SGA), large 
for gestational age (LGA) and appropriate for gestational 
age (AGA) pregnancies of amniotic fluid concentrations of 
sFas and FasL [13]. This could suggest no dependence of 
sFas and Fas L on fetal weight. Ashton suggested the crucial 
role of Fas/FasL role in trophoblast invasion, spiral artery 
remodeling and placental development [14]. 
In our study we found that parameters of apoptosis 
were higher in cord blood than in maternal blood. In fetal 
organism the process of multiplication of cells has higher 
level than apoptosis that allows fetal growth but in third 
trimester of pregnancy the process of multiplication of 
cells is low. We can suggest that this takes place because 
of processes of cells hypertrophy and probably all newly 
developed cells were unnecessary and destroyed.
An increase of apoptosis in placenta probably is caused 
by abnormal placentation and the effect we can observe 
as fetal growth restriction. In our study there were only 
AGA fetuses, so we could expect no increase of apoptotic 
processes in maternal blood [15]. 
We found statistical difference in sFas concentration be-
tween maternal blood and cord arterial and vein blood. Higher 
concentration was found in maternal blood and is possible 
that it is the protecting mechanism that plays role in placental 
protection from acceleration of apoptosis. Other observations 
show different results — higher cord blood sFas concentration 
measured at time of the delivery than in pregnant women 
[16].  As we think this difference could be caused by the way of 
delivery- spontaneous delivery or elective caesarean section.
There were no differences between arterial and vein blo-
od from umbilical cord. There was no other available data on 
comparison of arterial/vein ratio of sFas. But we can suggest 
that fetal blood circulation doesn’t demonstrate changes in 
contact of villi with maternal blood [13–15].
If compared Fas ligand [sFasL] concentrations in serum, 
different results were seen. In our study we compared con-
centration of Fas ligand [FasL] in maternal and cord blood 
sera. We found difference between maternal blood serum 
and both arterial and vein cord blood serum. Higher level 
of FasL was observed in maternal blood but we found no 
difference between cord vein and arterial blood.
Vrachinis et all found increased FasL expression in am-
niotic fluid in severe and very severe SGA fetuses that reflects 
the increased apoptosis in the fetus and placenta [13]. This 
observation could explain lower concentration of FasL in 
cord blood in uncomplicated pregnancy that protests fetal 
organism form apoptosis.
Umbilical serum level of FasL in observation of Randhava 
was significantly higher than maternal serum. There were no 
suggestions of the reason for this result [16, 17]. The results 
of Randhava was similar to our results.
The consequences of deregulation of Fas/FasL-mediated 
apoptosis linked to self-reactivity, immune dysfunction and 
malignant transformation and placental disfunction [17].
Maternal mean serum levels of sFas and sFasL were 
measured in preeclamptic pregnancies and compared to 
healthy pregnant women, showed no differences between 
compared groups [16, 18, 19].
From clinical point of view measurement of maternal 
blood FasL could not indicate the intensification of apop-
tosis process in fetal organism, but evaluation of maternal 
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to fetal blood proportion of FasL concentration could be 
helpful to establish normal causality of the relationship that 
still remains uncertain.
All presented by different authors data were obtained 
in small groups and further research is needed to evaluate 
normal concentrations of measured parameters for healthy 
pregnancy and SGA or preeclamptic patients [19]. There is 
so far little literature data to confirm either of these results. 
CONCLUSIONS
1. The study did not demonstrate significant differences 
in sFas and FasL concentration in cord arterial and vein 
blood that suggest no influence of fetal organism on 
apoptosis by sFas and FasL production 
2. Lowering of sFas concentration in fetal blood could 
mean the increase of apoptosis in fetal organism com-
paring to maternal.
3. Higher concentration of FasL in cord blood than in 
mothers suggested higher apoptosis intensification in 
fetal circulation and no influence of blood flow across 
placenta on its concentration.
4. Further studies were needed to establish normal values 
of sFas and FasL levels in early, second trimester and third 
trimester of physiological and pathological pregnancy.
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